McCormick & Company MKC
Consumer Defensive · Packaged Foods · Synthos Deep Dive · 2026-07-03
The Overview
McCormick is the company behind the spices and seasonings in your kitchen — the little red-capped McCormick jars, plus French's mustard, Frank's RedHot, Cholula, Old Bay, and Zatarain's. Half the business sells to shoppers in grocery stores; the other half sells flavors and seasonings in bulk to big food companies and restaurants. It's a slow, steady, recession-resistant business — people keep buying spices whether the economy is good or bad.
Is the stock cheap or expensive? Roughly fair — neither a bargain nor overpriced. You're paying about 16–18× next year's earnings for a company growing profits only about 9% a year, and it pays a solid 3.5% dividend. The stock has actually fallen about 31% over the past year, so it's much cheaper than it was — but it's still drifting down, not turning up.
Our verdict is Watch: a fine company, but there's no urgency to buy today.
Here's what our three scores mean in everyday terms:
- Downside Risk 5/10 (middle of the road). The business is stable and the stock is calm (it doesn't swing wildly), but the company carries a fair amount of debt and the price trend is still heading down.
- Growth Quality 4/10 (below average). It's profitable and dependable, but it grows slowly — think a steady walk, not a run.
- Exponential Potential 2/10 (low). This is a mature, century-old business. It won't multiply your money quickly; it's a bond-like, dividend-paying holding.
The one big worry: McCormick owes about 3.4 years of profits in debt, and cheaper store-brand ("private label") spices can eat into its sales when shoppers pinch pennies. Slow growth plus meaningful debt is why we say wait.
Putting a number on it: our fair-value estimate is $55 against a current price of $55.33 — a premium price for a business we still like.
Our summary metrics
Low beta (0.64) & defensive demand, but 3.4× net-debt/EBITDA and a live downtrend (−31% 12-mo).
Only ~5% forward revenue / ~9% EPS CAGR; solid 38% gross margin & 26% ROE, but slow.
Mature, decelerating spice compounder near its TAM ceiling — no exponential path.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Mature, decelerating spice compounder near its TAM ceiling — no exponential path.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $61.40 (high $72 / low $52; 11 Buy · 17 Hold · 2 Sell → Hold) — context, not our anchor |
| Valuation | ~18× FY26E EPS · 16× FY27E · EV/EBITDA 13.8× · EV/S 2.6× · div yield 3.5% |
| Technicals | Downtrend — $53.45, −30% off 52-wk high, below the 200-DMA ($60), RSI 64, −31% 12-mo (SPY +21%) |
| Conviction | Low — 0 expert voices in the KB; verdict rests on fundamentals + quant only |
| Position sizing | Income/defensive satellite only, ≤2%, if at all |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for MKC — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $55.33, 6% above the 50-day average ($52), 4% below the 200-day average ($57) — a mixed trend. 23% below the 52-week high of $72, 21% above the 52-week low of $46.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $55.33 is currently inside the band (band $51–$57).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 58.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.04, negative momentum.
Relative performance vs S&P 500 & its sector (XLP (sector)), set to 100 a year ago
Solid = MKC · dashed = S&P 500 · dotted = XLP (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
McCormick & Company (NYSE: MKC), founded 1889 and headquartered in Hunt Valley, Maryland, is the global leader in spices, seasonings, condiments, and flavors. Fiscal year ends November 30. The business runs in two segments:
- Consumer (branded, sold to retailers/e-commerce): McCormick, French's, Frank's RedHot, Cholula, Lawry's, Old Bay, Zatarain's, Gourmet Garden; plus Ducros/Schwartz/Kamis in EMEA and DaQiao in China.
- Flavor Solutions (B2B, sold to food manufacturers and foodservice): custom seasoning blends, coating systems, and technical flavor formulations for large clients.
Revenue mix (FY2025, from filings):
- By segment: Consumer $3.95B (58%) · Flavor Solutions $2.89B (42%). Consumer carries the higher margin; Flavor Solutions is stickier (embedded in customers' recipes) but grows with its clients.
- By geography: Americas $4.87B (71%) · EMEA $1.27B (19%) · Asia-Pacific $0.70B (10%). Heavily US/Americas-weighted; China (inside APAC) has been a persistent soft spot.
The strategic story is unglamorous and durable: pricing power on branded spices, a slow global volume grind, cost/supply-chain productivity ("CCI" savings program), and steady deleveraging after the 2020–21 Cholula/FONA acquisitions.
2. The expert thesis (no coverage — stated plainly)
There is no expert coverage of MKC in the Synthos knowledge base: total_claims = 0, zero net-bullish voices, zero traceable claim_ids. None of the panel voices Synthos tracks have made a durable, distilled call on McCormick.
That means this note carries no conviction-track signal — the verdict below is entirely fundamentals- and quant-driven (financial statements, analyst estimates, valuation, and technicals from FMP). We will not manufacture a thesis we cannot trace. If and when a tracked voice covers MKC, this section and the conviction rating will be updated.
For external context only (not a Synthos conviction input): the sell-side is split-to-cautious — 11 Buy, 17 Hold, 2 Sell (consensus Hold), price-target consensus $61.40. FMP's letter model rates the balance sheet weak (debt-to-equity score 2/5) but returns strong (ROE/ROA 5/5), netting an "A" headline that we treat skeptically given the leverage.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 5 · Moderate | Beta 0.64 and staple demand cushion the downside, and forward valuation (16–18×) is reasonable — but net-debt/EBITDA 3.4× is elevated, and the stock is in a live downtrend (−31% 12-mo, below the 200-DMA, −49% max drawdown from peak). |
| Growth Quality | 4 · Below-average | 38% gross margin, 26% ROE, ~$740M FCF and a 39-yr dividend-raise streak are high-quality — but forward revenue CAGR is only ~5% and EPS ~9%, and organic volume growth has been anemic. Quality is real; the growth is slow. |
| Exponential Potential | 2 · Low | A 137-year-old spice company at ~$14B with a mature TAM and decelerating growth. No accelerating second derivative, no multibagger path. It compounds like a bond-plus, not an exponential. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Volume growth re-accelerates (Frank's/Cholula/hot-sauce mix + Flavor Solutions win-back), gross margin pushes toward 40%, deleveraging continues. FY27E EPS beats to ~$3.55 (vs $3.30 cons); multiple re-rates to a staple-premium ~19×. | ~$68 (+27%) |
| Base (our anchor) | Estimates roughly hit — FY27E EPS ~$3.30; a dependable but slow ~mid-single-digit compounder with 3.4× leverage earns a ~16–17× multiple. | ~$55 (+3%) |
| Bear | Private-label share gains, US volume stays soft, China stays weak, and higher-for-longer rates keep pressuring the leveraged balance sheet. FY27E EPS misses to ~$3.05; multiple de-rates to ~13×. | ~$40 (−25%) |
Synthos fair value = the base case, ~$55 (+3%), with the full $40–$68 span as the honest range. Our anchor sits below the Street's $61.40 consensus — we are less willing to pay up for ~5% top-line growth carrying 3.4× leverage in a downtrend. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). MKC is a mature compounder with essentially no exponential profile:
- Forward growth: revenue CAGR FY25→FY30E ~5.3% ($6.84B → $8.84B); EPS CAGR ~9.5% ($2.94 → $4.63E) — the gap is buybacks, margin, and deleveraging, not volume.
- Acceleration (the 2nd derivative) is flat-to-negative: revenue was $6.32B (FY22) → $6.66B (FY23) → $6.72B (FY24) → $6.84B (FY25) — low-single-digit and not speeding up. This is the opposite of the accelerating profile Synthos rewards.
- Room to run: the global spice/flavor category is large but McCormick is already the #1 branded player — it is near its share ceiling in its core markets, so incremental growth is grind-it-out, not blue-sky TAM capture. Emerging-markets and Flavor Solutions are the only real expansion legs, and both are modest.
- Reinvestment runway: capex is a light ~3% of revenue; the company returns cash via dividends (~$483M/yr) rather than reinvesting for hyper-growth — the correct choice for a mature staple, but it caps upside.
Exponential Potential: Low (2/10). Own MKC — if at all — for its dividend and defensiveness, never for exponential upside. A small, accelerating flavor-tech name would score 8–9 here; a $14B, 5%-growth incumbent scores 2.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $6.84B, +1.7% (FY24 $6.72B, +0.9% on FY23 $6.66B). Steady but slow; the multi-year CAGR is low-single-digit.
- Quarterly trajectory: Q1 FY26 $1.874B → Q2 FY26 $1.937B (+16.7% YoY vs Q2 FY25 $1.660B) — a healthier recent print, and Q2 FY26 EPS $0.56 continuing (the headline $0.56 GAAP; note Q1 FY26 GAAP EPS of $3.78 was inflated by an $886M one-time discontinued-operations gain — strip it out for the true run-rate).
- Margins: gross 38.6% TTM (stable, a spice-branding hallmark), EBITDA margin 18.6%, operating ~15.3%, net ~22% GAAP TTM (flattered by the discontinued-ops gain; clean continuing net margin ~11–12%). Gross margin is the durable tell — pricing power holds.
- Earnings: FY25 net income $789M, EPS $2.94 (diluted $2.93) — essentially flat vs FY24 ($788M / $2.94). Earnings are not growing fast.
- Cash flow: FY25 operating CF $962M, capex −$222M, FCF ~$740M (FCF yield ~5.2%). FCF comfortably covers the ~$483M dividend (payout ~31% of earnings, ~65% of FCF).
- Balance sheet: total debt $4.0B, net debt $3.9B, net-debt/EBITDA ~3.4× — the single biggest quality knock. Deleveraging is underway (net debt fell from $4.4B FY23 → $3.9B FY25) but the balance sheet is not a fortress. Goodwill + intangibles are $8.6B (65% of assets) — legacy of the Cholula/FONA/RB Foods deals. Current ratio 0.78 (below 1, typical for a working-capital-efficient staple).
6. Valuation — priced in or room?
Important valuation caveat: FMP's headline TTM P/E of ~8.9× is distorted by the $886M one-time discontinued-ops gain in Q1 FY26 — ignore it. On clean, continuing earnings the picture is:
- P/E: ~18× FY26E ($3.09) → ~16× FY27E ($3.30) → ~12× FY30E ($4.63E). A staple growing EPS ~9% at ~16× forward is reasonable but not cheap — roughly fair.
- EV/EBITDA 13.8× and EV/Sales 2.6× — mid-range for premium packaged food; the branded-spice premium is justified by the 38% gross margin, but the 3.4× leverage means EV multiples matter more than equity multiples here.
- Dividend: yield 3.5%, 39 consecutive years of raises (a Dividend Aristocrat) — the core of the total-return case.
- PEG: forward ~1.3 (FMP) — fairly valued on growth-adjusted terms.
Street targets (context, not our anchor): consensus $61.40, high $72, low $52. Our $55 base-case FV is below consensus — we discount the Street's willingness to pay ~19× for ~5% top-line growth on a leveraged balance sheet in a downtrend. This is a fairly-valued, wait-for-a-better-entry name, not a value buy.
7. Technicals (computed from EOD price history)
- Trend: down. $53.45 sits above the 50-DMA ($48.4) but below the 200-DMA ($60.0) — a rally within a broader downtrend; the 50 is below the 200 (death-cross posture).
- Location: −30% off the 52-week high ($76.56), +17% off the 52-week low ($45.60), and a punishing −49% max drawdown from peak. This is a broken chart that has not yet repaired.
- Momentum: RSI(14) 64 — firm on the recent bounce, not overbought, but occurring below the 200-DMA (a lower-quality signal than an uptrend RSI).
- Relative strength (the tell): MKC −30.7% 12-mo vs SPY +20.6% and QQQ +30.3% — massive underperformance. Even 3-mo (+10.5%) lags QQQ (+22.0%). This is a serial laggard, not a leader.
- Read: technicals do not confirm a buy. A base above the 200-DMA (~$60) would be the constructive signal to watch for; until then the trend argues patience — consistent with the Watch verdict.
8. Moat & competitive position
McCormick's moat is real and old-fashioned: (1) brand + shelf dominance — the #1 branded spice player in the US with iconic marks (McCormick, French's, Frank's RedHot, Old Bay); (2) scale & distribution — the deepest spice supply chain globally, hard to replicate; (3) switching-cost stickiness in Flavor Solutions — its custom formulations are embedded in big food manufacturers' recipes. The durable 38% gross margin and 26% ROE are the moat made visible. The threats are unglamorous but real: private-label / store-brand spices (the perennial staple risk, sharper when consumers trade down), soft global volumes, and China weakness.
Peer set (market cap): J.M. Smucker $12.4B (closest branded-food comp), Hormel $13.8B, Campbell Soup $7.0B, Tyson Foods $21.0B, Bunge $20.7B, Lamb Weston $6.3B, Performance Food Group $17.8B, US Foods $23.0B, Coca-Cola FEMSA $22.6B. Within packaged food, MKC earns the highest gross margin and ROE in this group — the quality is not in question; the growth and leverage are.
9. Management, capital allocation & guidance
- Capital allocation: disciplined and shareholder-friendly for a mature staple — dividend first (~$483M/yr, 39-year raise streak, ~31% payout), modest buybacks (~$35M FY25), light capex (~3% of sales), and steady deleveraging (net debt $4.4B FY23 → $3.9B FY25). CEO Brendan Foley (Chairman, President & CEO). Appropriate priorities, but they confirm this is a return-of-capital story, not a growth-reinvestment one.
- Insider activity: the sampled window (through 2026-07-01) shows routine grant/award and phantom-stock activity (CEO Foley, CHRO Piper, several directors) — compensation mechanics, not conviction buying or alarming discretionary selling. Neutral signal.
- Management's own guidance: not available. The SEC 8-K route (Item 2.02) returned no usable earnings-release guidance text for this pull ("exhibit too thin"), so we do not summarize management's forward outlook here rather than fabricate it. When a clean earnings release is captured, this section will carry management's own (half-weighted, self-interested) guidance.
10. Catalysts & what to watch
- Next earnings: 2026-10-06 (Q3 FY26; Street EPS $0.75, revenue ~$1.98B). Key line: organic volume growth (has it turned positive and durable?) and gross margin trajectory.
- Volume vs price: the multi-year question is whether McCormick can grow volume, not just price — the Q2 FY26 +16.7% YoY revenue print is encouraging but needs to persist.
- Deleveraging: further reduction in net-debt/EBITDA below ~3.0× would meaningfully de-risk the equity.
- China / Flavor Solutions: recovery in the soft APAC region and Flavor Solutions client wins are the two real growth legs.
- Private-label pressure: watch for trade-down in a weak-consumer environment.
Thesis tripwires (what would change the call): a break and hold above the 200-DMA (~$60) on improving volumes would push toward a Buy — Tactical; conversely, negative organic volume plus stalled deleveraging would push toward Avoid.
11. Key risks
- Leverage (structural): net-debt/EBITDA 3.4× on a slow-growth base is the primary risk — higher-for-longer rates raise refinancing cost and limit flexibility.
- Slow / stalling growth: ~5% forward revenue CAGR with historically soft organic volume; if price-driven growth fades, the thesis weakens.
- Private-label / trade-down: store-brand spices are the perennial staple threat, sharper in a pinched-consumer environment.
- Downtrend / de-rating: the stock is below its 200-DMA and has underperformed the market by ~50 points over 12 months — momentum is against it.
- Goodwill/intangibles (65% of assets): acquisition-heavy balance sheet raises impairment risk if brand economics deteriorate.
- No expert coverage: the absence of any tracked-voice conviction means we have less independent corroboration than for a covered name — a genuine information gap, disclosed.
12. Verdict, position sizing & monitoring
Watch. McCormick is a legitimately high-quality, wide-moat, Dividend-Aristocrat spice franchise (38% gross margin, 26% ROE, ~$740M FCF, 39-year dividend-raise streak) — but three things keep it out of the Buy bucket today: (1) growth is slow and not accelerating (~5% revenue / ~9% EPS forward CAGR); (2) the balance sheet is leveraged at 3.4× net-debt/EBITDA; and (3) the stock is in a real downtrend (−31% 12-mo, below the 200-DMA) with our base-case fair value (~$55) roughly at the current price. There is no expert coverage in the Synthos KB, so this is a fundamentals/quant-only call — and the fundamentals say fine company, no urgency.
- Sizing: if owned at all, an income/defensive satellite, ≤2% — for the 3.5% yield and low-beta ballast, not for growth. Better entries likely below ~$48 (toward the 50-DMA / prior support) or on a confirmed break back above the 200-DMA.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print (next 2026-10-06). This verdict is logged as a tracked Synthos call as of 2026-07-03 at $53.45.
- Single biggest risk: a leveraged, slow-growth staple caught between private-label share loss and higher-for-longer rates.
Provenance & disclosures
- Traceability: 0 KB claims for MKC — no expert coverage exists in the Synthos knowledge base, and this note states that plainly. The verdict is fundamentals- and quant-driven. Fabricated conviction is structurally impossible (claim-ID reconciliation); here there are simply no claims to cite.
- Data as-of: fundamentals 2026-05-31 (Q2 FY26) · estimates & prices 2026-07-02/03. Forward figures are analyst consensus (FMP), labeled as estimates. The headline TTM P/E is distorted by a one-time discontinued-ops gain (Q1 FY26) — we use clean forward multiples throughout.
- Management caveat: management's own forward guidance was not available via the SEC 8-K route for this pull; none is summarized rather than fabricated.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").